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INTRODUCTION
Risk prediction in the practice of medical genetics is
probabilistic and not absolute.
The complexity of risk
predictions is increased by the complexity of systems biology
and an incomplete understanding of genetic and environmental
modifiers. Genotype does not predict phenotype even for rare
“single” gene or “simple” Mendelian disorders. The challenges
facing risk assessment in the medical context include lack of
understanding of the complexity of common, complex disorders,
the influence of genetic and environmental effects in
pharmacogenetics, and the difficulty of whole genome
approaches. The inability to give absolutes to our patients
means that often we give misinformation to our patients. This
article discusses how risk predictions in the genetics context
are compounded by complexity and incompleteness in our
understanding of systems biology.
GENETICS AND RISK PREDICTION
Genotype 1 cannot necessarily predict phenotype 2 for rare
“single” gene disorders 3 due to the complexity of the genome, 4
the proteome 5 interacting with the transcriptome, 6 and the
dynamically coupled systems that are involved. Beyond the
rare single gene disorders are common “complex” disorders,
which occur when the primary mutated gene effect diminishes
and two or more mutated genes have co-equal effects. Familiar
examples of complex disorders include obesity, heart disease,
diabetes, and cancer. Examining and predicting complex traits
is even more complicated than single gene traits, and poses the

1. Genotype is the genetic makeup of an individual. SCIENCE AND
TECHNOLOGY ENCYCLOPEDIA 231 (2000).
2. Phenotype is the physical characteristics of an individual resulting
from heredity. SCIENCE AND TECHNOLOGY ENCYCLOPEDIA, supra note 1, at
400.
3. A single gene disorder is a genetic disorder caused by one gene. The
Human Genome, http://genome.wellcome.ac.uk (last visited Mar. 28, 2007).
4. The genome is the entire complement of genetic material of an
individual coded in sequence by the DNA that makes up the chromosomes.
SCIENCE AND TECHNOLOGY ENCYCLOPEDIA, supra note 1, at 231.
5. The proteome is the entire complement of proteins in a given
biological organism or system. TOM STRACHAN & ANDREW P. READ, HUMAN
MOLECULAR GENETICS 3 553 (Garland Sci. 2004) (1996).
6. The transcriptome is the set of all messenger ribonucleic acid (mRNA)
molecules in a cell or set of cells. STRACHAN & READ, supra note 5, at 545.

MCCABE E & MCCABE L. Genomic Medicine: A Future Flooded with Risk Information. MINN.
J.L. SCI. & TECH. 2007;8(2):429-439.

2007]

FUTURE FLOODED WITH RISK INFORMATION

431

question of how to deal with them in providing medical care. 7
Despite their differences, however, common complex disorders
are not distinct from their rare single gene counterparts; both
are part of a continuum of increasing structural complexity.
Therefore, the tools developed for “single” gene disorders will be
adaptable to common complex diseases. Yet, some of the
challenges with common complex traits stem from the fact that
we do not understand the predictive significance of either the
genetics or the environment at this point.
Consider risk prediction for cystic fibrosis (CF). CF is an
autosomal recessive multisystem disease which can affect the
lungs, liver, pancreas, small intestine, reproductive tract, and
sweat glands of the skin. 8 CF is considered to be a single gene
disorder caused by mutations in the cystic fibrosis conductance
regulator (CFTR) chloride channel, which is encoded on
chromosome seven. 9 Lung disease is the leading cause of death
for patients with CF. 10 Thick mucus clogs the air passages of
the lungs and these clogged passages lead to chronic
respiratory infections and progressive destruction of the
lungs. 11 Mucus can also obstruct the pancreatic ducts, which
prevents digestive enzymes from entering the intestines,
eventually leading to loss of insulin production and diabetes
mellitus. 12 Research suggests a complexity of CFTR regulation
based on post-translational modification, protein kinases A and
C, and the availability of adenosine triphosphate (ATP). 13
The most common CFTR mutation in Caucasians is

7. Common complex diseases involve multiple genes and gene and
environment interactions, making diagnosis more difficult. Lori B. Andrews &
Erin Shaughnessy Zuiker, Ethical, Legal and Social Issues in Genetic Testing
for Complex Genetic Diseases, 37 VAL. U. L. REV. 793, 795 (2003).
8. See Francis S. Collins, Cystic Fibrosis: Molecular Biology and
Therapeutic Implications, 256 SCIENCE 774, 774 (1992).
9. See Collins, supra note 8, at 774.
10. See Am. Lung Ass’n, Cystic Fibrosis Fact Sheet, Nov. 2006,
http://www.lungusa.org/site/pp.asp?c=dvLUK9O0E&b=35042 (indicating that
respiratory failure is the “primary cause” of death for 90% of adults with CF).
11. See id.
12. See Paulus Ripa et al., The Relationship Between Insulin Secretion, the
Insulin-Like Growth Factor Axis and Growth in Children with Cystic Fibrosis,
56 CLINICAL ENDOCRINOLOGY 383 (2002).
13. For an extensive survey of research on the relationships between
CFTR functioning and translational modification, protein kinase, and ATP
levels, see generally Nat’l Ctr. for Biotech Info., Online Mendelian Inheritance
in Man, Cystic Fibrosis Transmembrane Conductance Regulator; CFTR,
www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=602421 (last visited Mar. 28,
2007).
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∆F508. 14 Originally, data suggested that ∆F508 was associated
with the most serious pulmonary symptoms, although this
putative association has not been supported by further research
based on information obtained from an increased numbers of
patients. 15 There is a lack of genotype-phenotype correlation,
and modifier genes determine the severity of ∆F508
homozygosity. 16 Drumm et al. studied the sequence variants in
ten genes previously reported to be modifiers of CF in patients
separated into groups with severe or mild lung disease. 17
Among the ten genes investigated they found significant
associations only for transforming growth factor β1 (TGFβ1). 18
TGFβ1 is involved in cell signaling and gene expression. 19 The
functions
of
TGFβ1
include
immune
responses,
proinflammatory and anti-inflammatory effects, growth and
differentiation, and extracellular matrix production. 20 TGFβ1
is also associated with other forms of lung disease, including
the progression of idiopathic pulmonary fibrosis, chronic
obstructive pulmonary disease, and asthma. 21 Drumm et al.
identified thirty-one additional markers, referred to as single
nucleotide polymorphisms (SNPs), around TGFβ1, and the
association between disease severity and TGFβ1 SNP variants
was confirmed. 22 Increased levels of the TGFβ1 protein were

14. Anselm A. Zdebik et al., Additional Disruption of the C1C-2 C1–
Channel Does Not Exacerbate the Cystic Fibrosis Phenotype of Cystic Fibrosis
Transmembrane Conductance Regulator Mouse Models, 279 J. BIOLOGICAL
CHEMISTRY 22276 (2004).
15. See, e.g., Joseph Zabner et al., CFTR ∆F508 Mutation Has Minimal
Effect on the Gene Expression Profile of Differentiated Human Airway
Epithelia, 289 AM. J. PHYSIOLOGY - LUNG CELLULAR & MOLECULAR
PHYSIOLOGY
L545
(2005),
available
at
http://ajplung.physiology.org/cgi/reprint/289/4/L545.
16. See, e.g., Mitchell L. Drumm et al., Genetic Modifiers of Lung Disease
in Cystic Fibrosis, 353 NEW ENG. J. MED. 1443, 1449-53 (2005).
17. Drumm et al. split a population of over eight hundred Delta F508
positive patients into two groups based upon the severity of their lung disease
symptoms. Id. at 1444. The first group belonged in the top quartile of
severity, while the second group represented the bottom quartile of severity.
Id. Drumm et al. then looked at variance of ten genes that allegedly
influenced the severity of CF and compared those results between these two
groups with the severe and mild lung disease. Id. at 1444-45.
18. Id. at 1446-48.
19. See id. at 1451.
20. Id. at 1451.
21. Id.
22. Id. at 1448-49.
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associated with more severe lung disease. 23
Research has also found that TGFβ1 reduces CFTR
expression in nasal polyps in patients who do not have cystic
fibrosis. 24 In 2005, a group from Spain headed by Virginie
Prulière-Escabasse furthered earlier work with TGFβ1, looking
at the connection between CF and nasal polyposis. Nasal
polyposis is a chronic inflammatory disease of the nasal mucosa
causing polyps in the nose and sinuses. 25 It can be primary,
meaning we do not know what it is associated with, but it also
has 50% prevalence with CF. 26 The hypothesis of PrulièreEscabasse et al. was that altered CFTR expression and function
was involved in the pathogenesis of nasal polyposis. 27 They
looked only at CFTR expression in non-CF patients and
compared the nasal polyp to the control mucosal epithelial
cells, finding that CFTR was expressed in the controlled nasal
epithelial cells but not in the nasal polyps. 28 Thus, TGFβ1
down-regulated CFTR expression and function measured by
chloride currents in the control but not the nasal polyps. 29
From this finding, they concluded that this was consistent with
studies in CF patients that showed high TGFβ1 secretors had
more severe lung disease. 30 These results are consistent with
another study that found that patients with CF who secreted
high levels of TGFβ1 had more severe lung disease. 31 Based on
these similar findings, there may be a story developing for
TGFβ1 as a genetic modifier. The research has found that
TGFβ1 functions in immune responses, 32 it has both

23. See id. at 1449-51.
24. Virginie Prulière-Escabasse et al., TGF- β1 Downregulates CFTR
Expression and Function in Nasal Polyps of Non-CF Patients, 288 AM. J. OF
PHYSIOLOGY - LUNG CELLULAR & MOLECULAR PHYSIOLOGY L77 (2005),
available at http://ajplung.physiology.org/cgi/reprint/288/1/L77 (comparing
CFTR expression in nasal polyps to normal mucosa in the same individual and
finding that CFTR is expressed in normal mucosa, but not in the nasal
polyps).
25. Id. at L77.
26. Id.
27. Id.
28. Id. at L78-L79, L81.
29. Id
30. Id. at L82.
31. Peter D. Arkwright et al., TGF- β1 Genotype and Accelerated Decline in
Lung Function of Patients with Cystic Fibrosis, 55 THORAX 459 (2000),
available at http://thorax.bmj.com/cgi/reprint/55/6/459.
32. See, e.g., S. Kakumu et al., Effect of Recombinant Human
Transforming Growth Factor β1on Immune Responses in Patients with
Chronic Hepatitis B, 13 LIVER 62 (1993).
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pro-inflammatory and anti-inflammatory effects, 33 it is
involved in growth and differentiation, 34 and it is involved in
extra-cellular matrix production. 35 In lung disease it has been
shown to be associated with progression of idiopathic
pulmonary fibrosis, 36 increased activity, chronic obstructive
pulmonary disease, 37 and asthma. 38 We have more work to do,
however, to confirm that there is a real biological relationship.
THE COMPLEXITY OF SYSTEMS BIOLOGY
Risk predictions are compounded by the complexity of
systems biology. 39 Systems biologists would argue that these
dynamic systems can be modeled and the models are amenable
to mathematical analyses, moving biology from a descriptive
science to a quantitative discipline. In the twentieth century,
physics developed the fundamental scientific basis for rigorous
applications in engineering by using mathematics. In the
twenty-first century, biology will provide the foundation for
applications in medicine, and these applications will
increasingly rely on the mathematical algorithms of systems
biology.
Medicine has begun to rely on mathematical algorithms in
ways that are transparent to both physician and patient. For
example, in the field of imaging, X-rays are no longer analogue,
which involves direct film exposure, but are now digital, and
the images, including sharpness and contrast, are based on
33. See Sharon M. Wahl, Transforming Growth Factor Beta (TGF-β) in
Inflammation: A Cause and a Cure, 12 J. CLINICAL IMMUNOLOGY 61 (1992).
34. See Mary E. Dickinson et al., Chromosomal Localization of Seven
Members of the Murine TGF-β Superfamily Suggests Close Linkage to Several
Morphogenetic Mutant Loci, 6 GENOMICS 505 (1990).
35. See Chie-Pein Chen et al., Hypoxia and Transforming Growth Factorβ1 Act Independently to Increase Extracellular Matrix Production by Placental
Fibroblasts, 90 J. CLINICAL ENDOCRINOLOGY & METABOLISM 1083 (2005).
36. See Moira K.B. Whyte, Genetic Factors in Idiopathic Pulmonary
Fibrosis: Transforming Growth Factor-β Implicated at Last, 168 AM. J. OF
RESPIRATORY & CRITICAL CARE MED. 410 (2003).
37. See L. Wu et al., Transforming Growth Factor-β1 Genotype and
Susceptibility to Chronic Obstructive Pulmonary Disease, 59 THORAX 126
(2004).
38. See Judith C.W. Mak et al., Analysis of TGF- β1 Gene Polymorphisms
in Hong Kong Chinese Patients with Asthma, 117 J. ALLERGY CLINICAL
IMMUNOLOGY 92 (2006).
39. Systems biology is the study of the relationships and interactions
between and among parts of biological systems. Ekat Kritikou, Forward, All
Systems Go!, 7 NATURES REVS. MOLECULAR CELL BIOLOGY 801, 801 (2006).
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calculations from the raw digital data. 40
Mathematical
algorithms are also crucial for ultrasonography, computerized
tomography (CT), magnetic resonance imaging (MRI), and
positron emission tomography (PET). These algorithms are
invisible to the physician, and a physician need not be a
mathematician to examine a digital image.
Systems dynamics are based on network architecture. 41
We used to think that biology was composed of random
networks, in which every node was connected to a similar
number of nodes. 42 However, biology is made up of scale-free
networks in which some nodes are more highly connected,
while others may have only one connection, a structure
described as “hub and spoke.” If a node that is a hub does not
function because of a mutation, then this takes out a significant
portion of the network. If a node with only one connection does
not function, however, the network is not affected as much, or
perhaps not at all. The internet is an example of a scale-free
network comprised of interconnected nodes. A number of these
nodes are highly connected; these are the critical servers.
Other nodes have just one connection, such as a desktop
computer or laptop device. If one computer stops working, it
will not affect the network. If a server node at a major
university goes down, all of the associated computers can no
longer access the other nodes, and are rendered useless for
networking purposes at that time.
Our knowledge of modifiers is incomplete. If we look at
cystic fibrosis we know about genetic modifiers, such as TGFβ1,
and environmental modifiers, such as colonization with
Pseudomonas bacteria.
These individual modifiers will
influence risk in a probabilistic manner.
However, risk
influences will vary depending upon the genetic make-up of the
individual. Therefore, to better understand the probabilistic
risks associated with a particular individual, we will need
whole genome information on large populations.

40. H.K. Huang et al., Digital Radiology at the University of California,
Los Angeles: A Feasibility Study, 16 J. DIGITAL IMAGING (2003).
41. See Albert-László Barabási & Zoltán N. Oltvai, Network Biology:
Understanding the Cell’s Functional Organization, 5 NATURE REVIEWS
GENETICS 101 (2004) (discussing a parallel between cellular function and
architectural features of other complex systems).
42. Id. at 104.
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PHARMACOGENETICS: AT THE INTERFACE OF
GENETICS AND ENVIRONMENT
Pharmacogenomics, the interface of genetics and
environment, is one of the first places where genomic medicine
is beginning to impact routine medical care. 43 This is the case
for molecular microbiology in particular, dealing with viruses
and bacteria for rapid diagnosis. The incidence of adverse drug
reactions (ADRs) in U.S. hospitals is 6.7%, and the incidence of
fatal ADRs is 0.3%. 44 Many drug side effects are not stochastic
events, because individuals are genetically predisposed to
The physician’s goal is to use
experience an ADR. 45
pharmacogenetics to predict and prevent ADRs and to optimize
an individual’s therapy.
Genomic medicine will be predictive, preventive, and
personalized. Testing devices will be required to acquire
genomic information in order to utilize pharmacogenomics.
The first microarray-based 46 testing device that was approved
by the Food and Drug Administration (FDA) on January 12,
2005 was the Roche AmpliChip CYP450. 47 The AmpliChip
CYP450 tests for genetic variation in the cytochrome P450
enzymes, CYP2D6 and CYP2C19, which metabolize drugs. 48
Drugs which impact these enzymes include the following
classes: anti-depressants, anti-psychotics, anticonvulsants,
cardiovascular medications, cancer chemotherapeutics, and
anti-malarial drugs. 49 Physicians typically give the same dose
to all adults, assuming identical drug metabolism in all adults.
43. Pharmacogenomics is the study of how genes modify drug metabolism.
STRACHAN & READ, supra note 6, at 610.
44. Jason Lazarou, et al., Incidence of Adverse Drug Reactions in
Hospitalized Patients, 279 J. AM. MED. ASS’N 1200 (1998).
45. Taisei Mushiroda et al., A Model of Prediction System for Adverse
Cardiovascular Reactions by Calcineurin Inhibitors Among Patients with
Renal Transplants Using Gene-Based Single-Nucleotide Polymorphisms, 50 J.
HUM. GENETICS 442 (2005).
46. A DNA microarray is a two-dimensional array of genes or gene
fragments set on a solid surface, such as glass, plastic or silicon chip for use in
monitoring gene expression levels. STRACHAN & READ, supra note 6, at 175.
47. Press Release, F. Hoffman-La Roche Ltd., Roche’s AmpliChip CYP450
Test Receives FDA Clearance-Microarray-Based Diagnostic Test. (Jan. 12,
2005),
in
Medical
News
Today,
available
at
medicalnewstoday.com/medicalnews.php?newsid=18822.
48. Li Li et al., New Cytochrome P4250 2D6*56 Allele Identified by
Genotype/Phenotype Analysis of Cryopreserved Human Hepatocytes, 34 DRUG
METABOLISM & DISPOSITION 1411 (2006).
49. Press Release, supra note 47.
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The AmpliChip CYP450 identifies different rates of
metabolism and classifies people as poor, intermediate, normal,
and ultra-rapid metabolizers. 50 Poor metabolizers suffer the
effects of toxic drug levels from prolonged and/or excessive drug
levels. Ultra-rapid metabolizers may not achieve any benefit
from a drug because they break down the drug before it has
time to work. The opposite phenomenon occurs for pro-drugs
that are metabolized to the therapeutically active compound.
WHOLE GENOME APPROACHES
The same kind of technology that is used for the
Cytochrome P450, the AmpliChip, can also be used for
whole-genome approaches.
Whole genome applications
currently use SNP microarrays or SNP chips. 51 SNPs (for
example, where a base A is changed to a C), usually occur in a
non-coding region that does not make a difference. 52 It may be
in a site that does not change to an amino acid. An SNP is not
a mutation, but a genetic marker. SNPs are distributed
throughout the genome, and SNP chips were originally
designed to identify SNP variation associated with different
phenotypes. SNP chips can also be used to look at the
presence, absence or amplification of a genomic region. SNP
chips combine molecular cytogenetics with the identification of
modifiers so that SNPs influencing the location of a mutation in
the DNA of an individual or a deletion in the DNA of an
individual can be examined.
We have been using SNP chips to screen for individuals
This
with the chromosome 22q11.2 deletion syndrome. 53
syndrome may include congenital cardiovascular defects,
craniofacial abnormalities, and hypoplasia of the thymus and
parathyroid glands. 54 This is the most frequent interstitial
deletion in humans – one in 4,000 live births – and 90% of
affected individuals have a three megabase region deleted. 55
This disorder shows a lack of genotype/phenotype correlation,
50. Id.
51. Itsik Pe’er et al., Evaluating and Improving Power in Whole-Genome
Association Studies Using Fixed Marker Sets, 38 NATURE GENETICS 663
(2006).
52. Id.
53. C.M. Stanczak et al., Single Chromosomal Copy Deletion in Digeorge
Syndrome Using a SNP Mapping Array, __HUMAN MUTATION__ (forthcoming
2007).
54. Id.
55. Id.
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meaning that patients with identical deletions have different
phenotypes, and patients with different deletions have identical
phenotypes. We have successfully used SNP chips to identify
patient deletions. Combining information about the deletion
with whole-genome SNP variation will enable us to improve
prediction of phenotype. However, risk predictions will remain
probabilistic and not absolute.
With a whole-genome approach, as an example, we can
identify patients’ deletions. This can be combined with the
knowledge of these polymorphisms, the SNPs in the deleted
region and genome-wide.
We can utilize whole-genome
information to improve prediction of the phenotype, that is, all
other SNPs. Despite all of this, risk predictions are still going
to be probabilistic and not absolute. It is just the way biology
is.
UNDERSTANDING AND UTILIZING COMPLEXITY
In order to understand and utilize complexity we need
systems biology. Systems biology is an attempt to quantify the
complexity of dynamically coupled robust networks. At this
time, however, we have limited information and methods; much
remains unknown. Systems biology will involve an incredible
volume of data and corresponding mathematical algorithms for
analysis. Despite the mathematical reduction of data, the
output will be voluminous. We need to find a way to represent
the output and the risks by genomic position or network
diagrams that physicians can easily interpret and patients can
easily understand.
CONCLUSION
Genomic medicine represents a future flooded with risk
information. We already recognize that we do not know all of
the information needed to counsel our patients in the genetics
clinic because this risk information is inherently probabilistic
and not absolute.
We must develop comprehensive
representations of this risk information in order to better
transfer that information to the general pediatrician and the
general practitioner for both the care of their patients and for
informing their patients. In pediatrics, parents tell us they do
not want a physician to dictate the care of their child, but want
to be partners in the care of their child. Parents want to
understand what this risk information means. Developing
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comprehensive representations of risk information will require
multi-disciplinary teams of geneticists, mathematicians,
engineers, and others to work together.

